Načítá se...
The Key to Unlocking the Chemotherapeutic Potential of PPARγ Ligands: Having the Right Combination
Despite extensive preclinical evidence that peroxisome proliferator-activated receptor (PPAR)γ activation protects against tumourigenesis, results from a few clinical trials using PPARγ ligands as monotherapy show modest success. In spite of this, several groups reported exciting results with therap...
Uloženo v:
| Hlavní autoři: | , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Hindawi Publishing Corporation
2012
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3395155/ https://ncbi.nlm.nih.gov/pubmed/22966225 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2012/946943 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|